drugset / Trial / NCT07527078

Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes

NCT07527078

Phase 3 Recruiting 350 enrolled Gan & Lee Pharmaceuticals.
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.

Timeline

Start
2026-04-07
Primary completion
2026-04-07
Completion
2027-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject GZR33 Unknown Subcutaneous
Comparator insulin degludec Protein / enzyme biologic Subcutaneous